Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
We performed silencing and overexpression studies of flavin containing monooxygenase (FMO) 3 in hyperlipidemic mouse models to examine its effects on trimethylamine N-oxide (TMAO) levels and atherosclerosis. Knockdown of hepatic FMO3 in LDL receptor knockout mice using an antisense oligonucleotide resulted in decreased circulating TMAO levels and atherosclerosis. Surprisingly, we also observed significant decreases in hepatic lipids and in levels of plasma lipids, ketone bodies, glucose, and insulin. FMO3 overexpression in transgenic mice, on the other hand, increased hepatic and plasma lipids. Global gene expression analyses suggested that these effects of FMO3 on lipogenesis and gluconeogenesis may be mediated through the PPARα and Kruppel-like factor 15 pathways. In vivo and in vitro results were consistent with the concept that the effects were mediated directly by FMO3 rather than trimethylamine/TMAO; in particular, overexpression of FMO3 in the human hepatoma cell line, Hep3B, resulted in significantly increased glucose secretion and lipogenesis. Our results indicate a major role for FMO3 in modulating glucose and lipid homeostasis in vivo, and they suggest that pharmacologic inhibition of FMO3 to reduce TMAO levels would be confounded by metabolic interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, there could be several problems with this approach as an accumulation of TMA leads to trimethylaminuria, which is characterized by fishy odor (similar to rotten fish) and induce inflammation [18,75,99].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“important regulators in host lipid and sterol metabolism, as well as atherosclerosis development”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“FMO3 inhibition is also accompanied by several untoward side effects, including hepatic inflammation”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“host hepatic FMO3, the primary FMO responsible for TMAO production”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
In the citing paper
“suppression of the host enzyme, FMO3, through antisense oligonucleotide-based approach, results in reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Shih et al., 2015
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Self-citationInsulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Self-citationIntestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Self-citationRepa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Bennett, B. J., Vallim, T. Q. D. A., Wang, Z., Shih, D. M., Meng, Y., Gregory, J., Allayee, H., Lee, R., Graham, M., Crooke, R., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.011 · Cited by 1,070
Self-citationLi, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733
Cited by
Items 101–200 of 342
Emerging roles of flavin monooxygenase 3 in cholesterol metabolism and atherosclerosis
Schugar, R. C., & Brown, J. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000215 · Cited by 65
Self-citationTargeting Trimethylamine N-Oxide: A New Therapeutic Strategy for Alleviating Atherosclerosis
Jing, L., Zhang, H., Xiang, Q., Shen, L., Guo, X., Zhai, C., & Hu, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.864600 · Cited by 72
“found that plasma TMAO levels in FMO3 knockout mice decreased (decreased by about 50% as compared with the control ASOtreated mice), leading to a reduced AS burden (84).”
BackgroundSerban, M.-C., Sahebkar, A., Mikhailidis, D. P., Toth, P. P., Jones, S. R., Muntner, P., Blaha, M. J., Andrica, F., Martin, S. S., Borza, C., et al. (2016) · Scientific Reports · doi:10.1038/srep19188 · Cited by 64
Self-citationRobinson-Cohen, C., Newitt, R., Shen, D. D., Rettie, A. E., Kestenbaum, B. R., Himmelfarb, J., & Yeung, C. K. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161074 · Cited by 63
“An indirect pathophysiologic effect of TMAO is evidenced by studies in mice overexpressing FMO3 that showed increases in lipogenesis and gluconeogenesis due to perturbation of PPARα and Kruppel-like factor 15 pathways, with a corresponding protective effect in FMO3 knockout mice [28].”
BackgroundFMO3 and its metabolite TMAO contribute to the formation of gallstones
Chen, Y., Weng, Z., Liu, Q., Shao, W., Guo, W., Chen, C., Jiao, L., Wang, Q., Lu, Q., Sun, H., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.06.016 · Cited by 66
From obesity through gut microbiota to cardiovascular diseases: a dangerous journey
Marzullo, P., Renzo, L. D., Pugliese, G., Siena, M. D., Barrea, L., Muscogiuri, G., Colao, A., & Savastano, S. (2020) · International Journal of Obesity Supplements · doi:10.1038/s41367-020-0017-1 · Cited by 72
Flavin-Containing Monooxygenases Are Conserved Regulators of Stress Resistance and Metabolism
Huang, S., Howington, M. B., Dobry, C. J., Evans, C. R., & Leiser, S. F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.630188 · Cited by 83
Hernández‐Alonso, P., Cañueto, D., Giardina, S., Salas‐Salvadó, J., Cañellas, N., Correig, X., & Bulló, M. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.04.002 · Cited by 72
Trimethylamine N‐oxide as a risk marker for ischemic stroke in patients with atrial fibrillation
Liang, Z., Dong, Z., Guo, M., Shen, Z., Yin, D., Hu, S., & Hai, X. (2019) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22246 · Cited by 57
DiNicolantonio, J. J., McCarty, M., & OKeefe, J. (2019) · Open Heart · doi:10.1136/openhrt-2018-000890 · Cited by 57
“One intriguing observation to emerge from TMAO research is that elevated hepatic expression of FMO3 boosts hepatic lipogenesis and gluconeogenesis, independent of its impact on TMAO levels; this might reflect FMO3’s ability to somehow support expression of FoxO1.”
BackgroundThe Gut Microbial Endocrine Organ in Type 2 Diabetes
Massey, W. J., & Brown, J. M. (2020) · Endocrinology · doi:10.1210/endocr/bqaa235 · Cited by 66
“After reaching portal circulation and trafficking to the liver TMA is oxidized to trimethylamineN-oxide (TMAO) by flavin-containing monooxygenases (FMOs), most predominantly FMO3 where it then reaches peripheral blood at a micromolar concentrations in humans and mice (88,89,92-95).”
BackgroundSelf-citationIntertwined Relationship of Mitochondrial Metabolism, Gut Microbiome and Exercise Potential
Imdad, S., Lim, W., Kim, J., & Kang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052679 · Cited by 75
“TMA is absorbed through the intestinal wall and transported to the liver for subsequent oxidation into TMAO, by the action of flavin-containing monooxygenases (FMO 1 and 3) [63,64].”
BackgroundYamagata, K., Hashiguchi, K., Yamamoto, H., & Tagami, M. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000747 · Cited by 59
Contribution of Gut Bacteria to Lipid Levels: Another Metabolic Role for Microbes?
Allayee, H., & Hazen, S. L. (2015) · Circulation Research · doi:10.1161/circresaha.115.307409 · Cited by 64
Self-citationDyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Theofilis, P., Vordoni, A., Koukoulaki, M., Vlachopanos, G., & Kalaitzidis, R. (2021) · American Journal of Nephrology · doi:10.1159/000518456 · Cited by 64
The Role of the Gut Microbiome and Trimethylamine Oxide in Atherosclerosis and Age-Related Disease
Hage, R. E., Al-Arawe, N., & Hinterseher, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032399 · Cited by 62
“High levels of plasma TMAO have been linked to an alteration of reverse cholesterol transport [16,24], hyperlipidemia and hyperglycemia [16,24,25], and the overexpression of inflammatory markers including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), c-reactive protein (CRP) [26,27], and insulin resistanc…”
BackgroundCicero, A. F. G., Colletti, A., von Haehling, S., Vinereanu, D., Bielecka-Dabrowa, A. M., Sahebkar, A., Toth, P. P., Reiner, Ž., Wong, N. D., Mikhailidis, D. P., et al. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422420000049 · Cited by 58
“Finally, it has been shown that elevated TMAO levels modify lipid metabolism through changes in the functionality of reverse cholesterol transport, sterol metabolism and modification of the quality and quantity of bile acids(226,227).”
BackgroundThe Nutritional Supplement L-Alpha Glycerylphosphorylcholine Promotes Atherosclerosis
Wang, Z., Hazen, J. E., Jia, X., Org, E., Zhao, Y., Osborn, L. J., Nimer, N. A., Buffa, J. A., Culley, M. K., Krajcik, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413477 · Cited by 54
Self-citationThe intestinal microbiome associated with lipid metabolism and obesity in humans and animals
Jian, Z., Zeng, L., Xu, T., Sun, S., Yan, S., Zhao, S., Su, Z., Ge, C., Zhang, Y., Jia, J., et al. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15740 · Cited by 57
“FMO3 is identified as a powerful modifier of cholesterol metabolism and RCT, and its deficiency leads to decreased glucose and lipid levels in the circulation and liver, whereas FMO3 overexpression has opposite effects (Shih et al., 2015).”
BackgroundMan, A. W. C., Xia, N., Daiber, A., & Li, H. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14850 · Cited by 54
“These suggest the attribution of diurnal variation to cardiovascular variables such as heart rate, blood pressure, and endothelial functions (Kawano et al., 2002; Otto et al., 2004; Panza, Epstein, & Quyyumi, 1991; Singh et al., 2003; Walters, Skene, Hampton, & Ferns, 2003).”
BackgroundDong, Z., Liang, Z., Guo, M., Hu, S., Shen, Z., & Hai, X. (2018) · Disease Markers · doi:10.1155/2018/1578320 · Cited by 57
Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy
Dannenberg, L., Zikeli, D., Benkhoff, M., Ahlbrecht, S., Kelm, M., Levkau, B., & Polzin, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107584 · Cited by 55
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators
Ferrara, S. J., & Scanlan, T. S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00868 · Cited by 48
Stroke and Vascular Cognitive Impairment: The Role of Intestinal Microbiota Metabolite TMAO
Tu, R., & Xia, J. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230203140805 · Cited by 47
Targeting the Microbiome in Heart Failure
Zabell, A., & Tang, W. H. W. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0528-4 · Cited by 51
Calorie restriction effects on circadian rhythms in gene expression are sex dependent
Astaf’ev, A. A., Patel, S. A., & Kondratov, R. V. (2017) · Scientific Reports · doi:10.1038/s41598-017-09289-9 · Cited by 50
Yu, Z., Zhang, L., Jiang, X., Xue, C., Chi, N., Zhang, T., & Wang, Y. (2020) · Journal of Food Science · doi:10.1111/1750-3841.15186 · Cited by 47
Wiese, G. N., Biruete, A., Moorthi, R. N., Moe, S. M., Lindemann, S. R., & Gallant, K. M. H. (2020) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2020.04.007 · Cited by 49
Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases
Schiattarella, G. G., Sannino, A., Esposito, G., & Perrino, C. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.08.003 · Cited by 48
Petriello, M. C., Hoffman, J. B., Sunkara, M., Wahlang, B., Perkins, J. T., Morris, A. J., & Hennig, B. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.03.016 · Cited by 49
“metabolism and reverse cholesterol transport [31, 32].”
BackgroundInfluentialTrenteseaux, C., Gaston, A., Aguesse, A., Poupeau, G., de Coppet, P., Andriantsitohaina, R., Khallou‐Laschet, J., Amarger, V., Krempf, M., Nobécourt, E., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309923 · Cited by 44
Liu, S., He, F., Zheng, T., Wan, S., Chen, J., Yang, F., Xu, X., & Pei, X. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100014 · Cited by 46
The Possible Role of Probiotic Supplementation in Inflammation: A Narrative Review
Colletti, A., Pellizzato, M., & Cicero, A. F. G. (2023) · Microorganisms · doi:10.3390/microorganisms11092160 · Cited by 51
Intestinal Microbiota Metabolism and Atherosclerosis
Liu, T.-X., Niu, H.-T., & Zhang, S.-Y. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.167362 · Cited by 43
“[37] Furthermore, the knockdown of Fmo3 using antisense oligonucleotide in mice also attenuated atherosclerosis.[57] The knockdown of Fmo3 not only resulted in decreased TMAO levels but also regulated both lipid metabolism and inflammation, thereby attenuating atherosclerosis.”
BackgroundThe Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 47
Self-citationAssociation of Gut Microbiota-Dependent Metabolite Trimethylamine N-Oxide with First Ischemic Stroke
Sun, T., Zhang, Y., Yin, J., Peng, X., Zhou, L., Huang, S., Wen, Y., Cao, B., Chen, L., Li, X., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.55962 · Cited by 47
Gao, Y., Chen, H., Li, J., Ren, S., Yang, Z., Zhou, Y., & Xuan, R. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24333 · Cited by 45
Choline metabolites: gene by diet interactions
Smallwood, T., Allayee, H., & Bennett, B. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000259 · Cited by 42
Self-citationRelationship between intestinal microbiota, diet and biological systems: an integrated view
Ferreira, R. D. S., Mendonça, L. A. B. M., Ribeiro, C. F. A., Calças, N. C., Guimarães, R. D. C. A., do Nascimento, V. A., Freitas, K. D. C., Carvalho, C. M. E., de Castro, A. P., & Franco, O. L. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1836605 · Cited by 49
“Although CVD is related to dyslipidemia, the intestinal microbiota also substantially interferes with the host’s lipid metabolism (Fu et al. 2015; Shih et al. 2015).”
BackgroundKrueger, E. S., Lloyd, T. S., & Tessem, J. S. (2021) · Nutrients · doi:10.3390/nu13082873 · Cited by 42
“TMAO supplemented high fat diet fed mice had decreased glycogen synthesis and FMO3 knockout mice with reduced TMAO levels had increased synthesis which connects TMAO to hepatic insulin resistance [161,162].”
BackgroundInfluentialChen, C., Leu, H., Wang, S., Tsai, S., Chou, R., Lu, Y., Tsai, Y., Kuo, C., Huang, P., Chen, J., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0115 · Cited by 43
Role of the gut microbiota in complications after ischemic stroke
Zhang, J., Ling, L., Xiang, L., Li, W., Bao, P., & Yue, W. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1334581 · Cited by 48
Bresciani, L., Dall’Asta, M., Favari, C., Calani, L., Rio, D. D., & Brighenti, F. (2018) · Food & Function · doi:10.1039/c8fo01778f · Cited by 40
Trimethylamine-N-oxide and its biological variations in vegetarians.
Obeid, R., Awwad, H. M., Keller, M., & Geisel, J. (2017) · European Journal of Nutrition · doi:10.1007/s00394-016-1295-9 · Cited by 38
TMAO and diabetes: from the gut feeling to the heart of the problem
Jaworska, K., Kuś, M., & Ufnal, M. (2025) · Nutrition and Diabetes · doi:10.1038/s41387-025-00377-8 · Cited by 48
“…that FMO3, the enzyme responsible for converting TMA into TMAO, might exert harmful effects independently of TMAO levels [76], as it may directly boost hepatic lipogenesis and gluconeogenesis [146], and support the expression of FoxO1, a key node responsible for the insulin-resistant state [75].”
Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease
Zhao, Y., & Wang, Z. (2020) · Journal of Laboratory and Precision Medicine · doi:10.21037/jlpm.2020.01.01 · Cited by 44
“Further, atherosclerotic lesion area was decreased with the decreased plasma TMAO (58), suggesting the TMAO metaorganismal pathway is linked to atherosclerosis.”
BackgroundSelf-citationShi, W., Huang, Y., Zhou, Y., Zhu, L., & Yu, B. (2021) · Bioscience Reports · doi:10.1042/bsr20204250 · Cited by 42
Shi, C., Pei, M., Wang, Y., Chen, Q., Cao, P., Zhang, L., Guo, J., Deng, W., Wang, L., Li, X., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.060 · Cited by 39
The microbiome and its pharmacological targets: therapeutic avenues in cardiometabolic diseases
Neves, A. L., Chilloux, J., Sarafian, M. H., Rahim, M. B. A., Boulangé, C. L., & Dumas, M.-E. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.013 · Cited by 36
Bordoni, L., Samulak, J. J., Sawicka, A. K., Pelikant‐Małecka, I., Radulska, A., Lewicki, Ł., Kalinowski, L., Gabbianelli, R., & Olek, R. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-75633-1 · Cited by 38
Koppe, L., & Soulage, C. O. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.025 · Cited by 42
Wei, H., Zhao, M., Huang, M., Li, C., Gao, J., Yu, T., Zhang, Q., Shen, X., Liang, J., Ni, L., et al. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0857-2 · Cited by 35
“Global gene expression analyses have suggested that FMO3 has broad effects on lipogenesis and gluconeogenesis mediated through the PPARα and Kruppel-like factor 15 pathways and the beiging of white adipose tissue [11,27].”
BackgroundSelf-citationKim, S.-J., Bale, S., Verma, P., Wan, Q., Ma, F., Gudjonsson, J. E., Hazen, S. L., Harms, P. W., Tsou, P., Khanna, D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104669 · Cited by 37
“Knockdown of FMO3 in low-density lipoprotein receptor-knockout mice uncovered a role for FMO3 in glucose and lipid homeostasis (Shih et al., 2015).”
BackgroundSelf-citationZhang, Q., Guo, X., Xie, C., Cao, Z., Wang, X., Liu, L., & Yang, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105884 · Cited by 36
Antioxidant Role of Probiotics in Inflammation-Induced Colorectal Cancer
Hamamah, S., Lobiuc, A., & Covașă, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169026 · Cited by 36
“Once produced, TMA is oxidized to Trimethylamine-N-Oxide (TMAO) in the liver by hepatic flavin monooxygenase [230].”
BackgroundModulation of Gut Microbiota in Pathological States
Wang, Y., Wang, B., Wu, J., Jiang, X., Tang, H., & Nielsen, O. H. (2017) · Engineering · doi:10.1016/j.eng.2017.01.013 · Cited by 41
“The underlying mechanism that describes the association between TMAO-producing gut microbes and coronary heart disease is attributed to the action of a TMAO-producing enzyme, flavin monooxygenase-3, which is involved in the perturbations of reverse cholesterol transport and which has the effect of reorganizing the tot…”
BackgroundSelf-citationWang, F., Xu, J., Jakovlić, I., Wang, W., & Zhao, Y. (2019) · Food & Function · doi:10.1039/c9fo01853k · Cited by 34
Vitamin D Decreases Plasma Trimethylamine‐N‐oxide Level in Mice by Regulating Gut Microbiota
Wang, X., Li, X., & Dong, Y. (2020) · BioMed Research International · doi:10.1155/2020/9896743 · Cited by 42
“Both clinical and animal studies have shown that FMO3 oxidizes TMA to TMAO in the liver, and its expression is the main regulator of the TMAO level [23].”
BackgroundInactivation mechanism of N61S mutant of human FMO3 towards trimethylamine
Gao, C., Catucci, G., Castrignanò, S., Gilardi, G., & Sadeghi, S. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-15224-9 · Cited by 33
Koh, Y., Li, S., Chen, P., Wu, J.-C., Nagabhushanam, K., Ho, C., & Pan, M. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900514 · Cited by 31
Self-citationRamireddy, L., Tsen, H., Chiang, Y.-C., Hung, C.-Y., Chen, F., & Yen, H. T. (2021) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2021.100043 · Cited by 39
Mihuţa, M. S., Paul, C., Borlea, A., Roi, C. M., Pescari, D., Velea-Barta, O.-A., Mozos, I. M., & Stoian, D. L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1253584 · Cited by 35
Bjørnestad, E. Ø., Olset, H., Dhar, I., Løland, K. H., Pedersen, E. R., Svingen, G. F. T., Svardal, A. M., Berge, R. K., Ueland, P. M., Tell, G. S., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13067 · Cited by 31
Li, D., Kirsop, J., & Tang, W. H. W. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0634-1 · Cited by 29
New Insight into the Dietary Cause of Atherosclerosis: Implications for Pharmacology
Spector, R. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233296 · Cited by 29
Plasma trimethylamine‐N‐oxide following supplementation with vitamin D or D plus B vitamins
Obeid, R., Awwad, H. M., Kirsch, S. H., Waldura, C., Herrmann, W., Graeber, S. M., & Geisel, J. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600358 · Cited by 31
“TMAO has been shown to balance cholesterol reverse transport, intestinal absorption, and intake [15, 16].”
BackgroundHu, C., Wang, P., Yang, Y., Li, J., Jiao, X., Yu, H., Wei, Y., Li, J., & Qin, Y. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.560201 · Cited by 31
The microbial-mammalian metabolic axis: a critical symbiotic relationship
Chilloux, J., Neves, A. L., Boulangé, C. L., & Dumas, M. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000284 · Cited by 33
Guo, D., Shen, Y., Li, W., Li, Q., Miao, Y., & Zhong, Y. (2020) · Aging · doi:10.18632/aging.102666 · Cited by 26
“Some studies suggest that the FMO3/TMAO pathway is correlated with diabetes-associated cardiovascular disease [39], and others indicate that the effects of FMO3 on modulating glucose, lipid, and inflammation are independent of TMA/TMAO metabolism [40, 41].”
BackgroundMetabolomics in Gestational Diabetes Mellitus: A Review
XIE, J., LI, L., & XING, H. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.12.005 · Cited by 26
Friedrich, N., Skaaby, T., Pietzner, M., Budde, K., Thuesen, B. H., Nauck, M. A., & Linneberg, A. R. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.007 · Cited by 28
Gut Microbe-Generated Metabolite Trimethylamine-N-Oxide and Ischemic Stroke
Li, Z., He, X., Fang, Q., & Yin, X. (2024) · Biomolecules · doi:10.3390/biom14111463 · Cited by 31
“FMO3 is a key enzyme in TMAO production, and its knockdown not only reduces the circulating TMAO concentration but also leads to changes in lipid and cholesterol metabolism [46,60].”
Senthong, V., Kiatchoosakun, S., Wongvipaporn, C., Phetcharaburanin, J., Tatsanavivat, P., Sritara, P., & Phrommintikul, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-93803-7 · Cited by 28
Metabonomic profiling of chronic intermittent hypoxia in a mouse model
Conotte, S., Tassin, A., Conotte, R., Colet, J., Boudjeltia, K. Z., & Legrand, A. (2018) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2018.02.015 · Cited by 26
“Recently, metabonomics, a new complementary tool to genomics and proteomics, appears as one of the most powerful predictive technique to determine the systemic biochemical profiling by analysing tissues and biofluids such as plasma or urine (Nicholson et al., 2002; Shockcor and Holmes, 2002).”
MethodWu, X., Li, C., Mariyam, Z., Jiang, P., Zhou, M., Zeb, F., Haq, I. U., Chen, A., & Feng, Q. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26600 · Cited by 25
“For example, atherosclerosis lesion area is decreased in FMO3 ASO-treated mice; however, lesion size is increased when FMO3 is overexpressed in transgenic mice compared with control group (Shih et al., 2015).”
BackgroundWang, J., Long, C., Zhang, H., Zhang, Y., Wang, H., Yue, H., Wang, X., Wu, S., & Qi, G. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16472 · Cited by 28
“In mice, natural variations in FMO3 expression alter TMAO levels and lipid metabolism [8].”
BackgroundInfluentialRole of gut microbe-derived metabolites in cardiometabolic diseases: Systems based approach
Cao, Y., Aquino-Martínez, R., Hutchison, E. R., Allayee, H., Lusis, A. J., & Rey, F. E. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101557 · Cited by 29
Self-citationThe Role of the Microbiota in the Diabetic Peripheral Artery Disease
Biscetti, F., Nardella, E., Cecchini, A. L., Landolfi, R., & Flex, A. (2019) · Mediators of Inflammation · doi:10.1155/2019/4128682 · Cited by 26
Gil‐Gómez, A., Brescia, P., Rescigno, M., & Romero‐Gómez, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723752 · Cited by 26
Eyileten, C., Jarosz-Popek, J., Jakubik, D., Gąsecka, A., Wolska, M., Ufnal, M., Postula, M. A., Toma, A., Lang, I. M., & Siller-Matula, J. M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.728724 · Cited by 24
“Dyslipidaemia 165 (57) 129 (58) 36 (54) 0.”
Massey, W. J., Osborn, L. J., Banerjee, R., Horak, A. J., Fung, K. K., Orabi, D., Chan, E. R., Sangwan, N., Wang, Z., & Brown, J. M. (2022) · Metabolites · doi:10.3390/metabo12040364 · Cited by 22
“In our study, we have chosen to take a hepatocentric view given the literature precedent of TCDD pathology and FMO3 function in the liver [5,12,20,22,24,41,43,73,74].”
BackgroundMethodSelf-citationWu, X., Lin, D., Li, Q., Cai, J., Huang, H., Xiang, T., & Tan, H. (2023) · Aging · doi:10.18632/aging.204973 · Cited by 23
Diet, Microbes, and Murine Atherosclerosis
Getz, G. S., & Reardon, C. A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311513 · Cited by 25
“Although most of this discussion deals with the role of the choline-TMA-TMAO axis on atherogenesis, it is clear from recent work that this axis plays an important role in glucose and lipid metabolism, as well as cholesterol homeostasis.(6,15,16) Indeed, this work may provide some insight into the correlation of choles…”
BackgroundSong, J., Huang, M., Shi, X., Li, X., Chen, X., He, Z., Li, J., Xu, G., & Zheng, J. (2021) · Animals · doi:10.3390/ani12010048 · Cited by 27
“In mice, the natural variability of FMO3 not only reduces TMAO production but also stimulates the RCT process to promote cholesterol efflux [15].”
BackgroundSynergic interactions between berry polyphenols and gut microbiota in cardiovascular diseases
Iqbal, A. Z., Javaid, N., & Hameeda, M. (2022) · Mediterranean Journal of Nutrition and Metabolism · doi:10.3233/mnm-220071 · Cited by 21
Yu, J., Zhang, T., Gao, X., Xue, C., Xu, J., & Wang, Y. (2017) · RSC Advances · doi:10.1039/c7ra10248h · Cited by 21
Binding of methimazole and NADP(H) to human FMO3: In vitro and in silico studies
Gao, C., Catucci, G., Gilardi, G., & Sadeghi, S. J. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.06.104 · Cited by 20
“Although complete inhibition of hFMO3 is undesirable, its reduced activity might be beneficial [15, 16].”
BackgroundWinter, M., Bretschneider, T., Thamm, S., Kleiner, C., Grabowski, D., Chandler, S., Ries, R., Kley, J. T., Fowler, D., Bartlett, C., et al. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219838216 · Cited by 19
Coronary heart disease and intestinal microbiota
Liu, L., He, X., & Feng, Y. (2019) · Coronary Artery Disease · doi:10.1097/mca.0000000000000758 · Cited by 25
Endogenous Roles of Mammalian Flavin-Containing Monooxygenases
Phillips, I. R., & Shephard, E. A. (2019) · Catalysts · doi:10.3390/catal9121001 · Cited by 19
“Studies on mice have identified potential roles for FMO3 in cholesterol metabolism and reverse cholesterol transport [67,95] and in glucose and lipid homeostasis [96].”
BackgroundGut Microbiota and Heart, Vascular Injury
Zeng, C., & Tan, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2385-4_8 · Cited by 21
Chilloux, J., Brial, F., Everard, A., Smyth, D. R., Andrikopoulos, P., Zhang, L., Plovier, H., Myridakis, A., Hoyles, L., Moreno‐Navarrete, J. M., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01413-8 · Cited by 26
“…mice a 60% kcal HFD with a time frame comparable to those used in subsequent experimental designs using osmotic minipumps for constant subcutaneous TMA FMO3 inactivation was beneficial for several metabolic outcomes 21–24 , strongly suggesting that TMA and TMAO have distinct biological roles.”
Trimethylamine N-oxide: role in cell senescence and age-related diseases
Zhang, L., Yu, F., & Xia, J. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-03011-w · Cited by 26
“1 3 oligonucleotides in mice not only decreased TMAO levels but also regulated lipid metabolism and inflammation [145].”
BackgroundCrosstalk between the Gut and Brain in Ischemic Stroke: Mechanistic Insights and Therapeutic Options
Huang, W., Zhu, L., Song, W., Zhang, M., Teng, L., & Wu, M. (2022) · Mediators of Inflammation · doi:10.1155/2022/6508046 · Cited by 20
“Studies using animal models have shown that inhibiting FMO3 activity decreases TMAO levels and inhibits atherosclerosis [90].”
BackgroundRamos, L. F., da Silva, C. M., Pansa, C. C., & Moraes, K. C. M. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1820321 · Cited by 20
Wu, B., Liu, Y., Li, H., Zhu, L., Zeng, L., Zhang, Z., & Peng, W. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.391305 · Cited by 24
“Notably, knockdown of FMO3 in mice reduces plasma TMAO concentrations while simultaneously controlling inflammation and lipid metabolism (Shih et al., 2015; Warrier et al., 2015).”
BackgroundEffect of three oral pathogens on the TMA-TMAO metabolic pathway
Wang, X., Chen, L., Teng, Y., Xie, W., Huang, L., Wu, J., Wang, H., & Xie, S. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1413787 · Cited by 21
“From there, TMA enters the bloodstream, is transported to the liver via the portal circulation, and is oxidized by hostenzymecalledhepatic fl avin-containingmonooxygenase3(FMO3) into TMAO (Shih et al., 2015).”
BackgroundSelf-citationProkopienko, A. J., West, R. E., Schrum, D. P., Stubbs, J. R., Leblond, F. A., Pichette, V., & Nolin, T. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-52032-9 · Cited by 17
Choline in immunity: a key regulator of immune cell activation and function
Maia, C., Fung, C. W., & Sánchez‐López, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1617077 · Cited by 20
“In the large intestine, gut microbiota, including Firmicutes and Proteobacteria, convert choline into trimethylamine (TMA) (8), which is subsequently absorbed and oxidized in the liver by fl avin monooxygenase 3 (FMO3) into trimethylamine-N-oxidase (TMAO) (9).”
Martínez‐Montoro, J. I., Kuchay, M. S., Román, A. B., Martínez‐Sánchez, M. A., Frutos, M. D., Fernández‐García, J. C., & Ramos‐Molina, B. (2021) · Obesity Reviews · doi:10.1111/obr.13367 · Cited by 16
“TMAO is found to contribute to the development of many metabolic diseases, such as cardiovascular disease, T2DM, and NAFLD, as it is a main modulator of insulin resistance, lipid metabolism and liver inflammation.(90) Indeed, several clinical studies have found that the circulating levels of TMAO are associated with t…”
Background
Metadata
- Authors
- Shih, D. M., Wang, Z., Lee, R., Meng, Y., Che, N., Charugundla, S., Qi, H., Wu, J., Pan, C., Brown, J. M., Vallim, T., Bennett, B. J., Graham, M., Hazen, S. L., & Lusis, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Cleveland Clinic (US)
- Ionis Pharmaceuticals (United States) (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Lusis, Aldons J.
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 56
- Issue
- 1
- Pages
- 22-37
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC4274068
- OpenAlex
- W2163604084
- Cited by
- 335
- References
- 46
- Citations by year
- 2026: 17 · 2025: 19 · 2024: 18 · 2023: 20 · 2022: 43 · 2021: 36 · 2020: 44 · 2019: 33 · 2018: 28 · 2017: 28 · 2016: 33 · 2015: 16
- FWCI
- 29.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 2088 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- UNC Libraries
- Funders
- National Institutes of Health (HL‐28481, HL30568, HL113452)
- National Heart, Lung, and Blood Institute (HL3 0568, HL28481, P01HL030568, HL113452, P20HL113452, P01HL028481)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- FMO3, trimethylamine N-oxide, atherosclerosis, glucose metabolism, lipid metabolism, hepatic lipogenesis, gluconeogenesis, PPARα, KLF15, hyperlipidemia, LDL receptor knockout mice, hepatic lipid accumulation, insulin, ketone bodies
- MeSH terms
- Animals, Bile Acids and Salts, DNA-Binding Proteins, Feces, Female, Glucose, Homeostasis, Humans, Insulin, Intestinal Mucosa, Lipoproteins, Liver, Methylamines, Oxygenases, Receptors, LDL, Transcription Factors, Gene Expression Regulation, Enzymologic, Cell Line, Tumor, PPAR alpha, Lipogenesis, Atherosclerosis, Lipid Metabolism, Mice, Kruppel-Like Transcription Factors, Gene Knockdown Techniques, Gene Knockout Techniques, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.